Pro-inflammatory Cytokines in Facioscapulohumeral Muscular Dystrophy (CYTOKINE-FSH)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-30

Study Completion Date

2021-05-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The facial-glenohumeral muscular dystrophy type 1 (DMFSH1) is characterized by a selective and asymmetrical involvement of the facial muscles, the shoulder girdle and the anterolateral lodge legs. Genetically, the disease is transmitted in an autosomal dominant manner and is caused by a pathogen contraction of repeat units (UR) say D4Z4 localized to the telomeric portion of chromosome 4qA. The loss of UR causes hypomethylation of DNA and chromatin relaxation of the region that lead to inappropriate expression of DUX4 retrogene highly toxic. The inappropriate expression induces a T cell reaction inflammatory response that participate and increase muscle damage. In favor of this hypothesis, several muscle MRI studies have shown that atrophy and fibro-adipose degeneration (hyper signal in T1) were preceded by the appearance of muscle inflammation (hyper signal T2STIR) confirmed on histologically and dysregulation of genes involved in adaptive and innate immunity. scientific hypothesis and potential benefits: the investigateur hypothesize that in patients of DMFSH1, the immune system cells may participate in the pathophysiology of the disease through changes in serum secretion of one or more cytokines and / or a modification of the response of inflammatory cells in some cell damage stimuli. Design: this is a single-center pilot study, interventional. In this study, the investigator will assay the serum cytokines and changes in peripheral blood cells of the expression of cytokines in response to some stimuli in 20 patients with Type 1 DMFSH genetically confirmed at an intermediate stage of clinical disease (kept walking, but at least one muscle of lower limbs reached) and compare with controls from the CYTOKINAGE study. The investigator will also carry patients clinical testing (MMT sum score) and functional (6minute test march MFM) and a MRI not injected whole body (T1 sequences + and T2STIR) to study the relationship between these parameters and secretion cytokines or serum in response to certain stimuli Main objective: to compare serum levels of IL-6 in patients with DMFSH and controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Morphology and Functional Magnetic Resonance Imaging (MRI) Muscle Patients With Muscular Dystrophy Type FSHD Benefiting a Physical Training Introduced.

NCT01990976

Muscular Dystrophy Facioscapulohumeral

COMPLETED

A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD

NCT01437345

Facioscapulohumeral Muscular Dystrophy

COMPLETED

Routine Health Care of Patients With FSHD

NCT02622438

Primary Disease Fascioscapulohumeral Dystrophy (FSHD)

COMPLETED NA

Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1

NCT06222827

Facioscapulohumeral Muscular Dystrophy 1

ACTIVE_NOT_RECRUITING PHASE2

New Clinical Outcome Measures to Remotely Evaluate Patients With FacioScapuloHumeral Muscular Dystrophy

NCT05812144

Type 1 Facioscapulohumeral Muscular Dystrophy

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Muscular Dystrophies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Interventional pilot study

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Facioscapulohumeral muscular dystrophy

Adult ambulant patients with facioscapulohumeral muscular dystrophy type 1 (FSHD1)

Group Type EXPERIMENTAL

cytokines dosage

Intervention Type OTHER

Mesure of cytokines concentration in serum

test of walk

Intervention Type PROCEDURE

patient must walk during 6 minutes on a flat surface

Manual muscular test

Intervention Type PROCEDURE

test performed to evaluate the patient muscular weakness

Motrice fonction mesurement

Intervention Type PROCEDURE

scale allowing the evaluation of patient posture and upper body movements

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cytokines dosage

Mesure of cytokines concentration in serum

Intervention Type OTHER

test of walk

patient must walk during 6 minutes on a flat surface

Intervention Type PROCEDURE

Manual muscular test

test performed to evaluate the patient muscular weakness

Intervention Type PROCEDURE

Motrice fonction mesurement

scale allowing the evaluation of patient posture and upper body movements

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

biological analysis

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male or female age 18 to 75
* suffering from genetically confirmed FSHD1 (\<11 D4Z4 repeat units on permissive chromosome 4 allele)
* ambulant or walking with assistance
* Manual Muscle Testing ≥4 for 1 of lower limb muscles

Exclusion Criteria

* pregnancy or breast feeding
* stay in tropical/subtropical country within 3 months
* physical exercice within 10 hours
* specific diet (e.g. hypocaloric or cholesterol lowering diet)
* regular alcohol consumption; drug consumption within 3 months
* immunosuppressive or immonumodulating drug within 2 weeks or for more than 3 months withing last 6 months
* vaccination, blood transfusion of immunoglobulin treatment within 3 months
* infection within 3 weeks; HIV, HBV, HCV seropositivity
* chronic inflammatory and/or autoimmune or allergic disease from the gut (Crohn disease, ulcerative colitis), skin (psoriasis, atopic dermatitis), joints (rhumatoid arthritis), nervous system (multiple sclerosis), diabetes type I and II
* neurodegenerative disorders (Alzheimer's or Parkinson's diseases)
* diagnosed cancer not under remission for at least 5 years
* participation in the last 3 months in a research clinical trial with exposure to a pharmaceutical product or a medical device
* muscular MRI contraindication

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No